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ABSTRACT 
Rheumatoid Arthritis (RA) pharmacotherapy may impact mental health (MH) outcomes by 
improving pain and stiffness; and potentially via targeting inflammatory processes common to RA 
and depression. The objectives of this review were to i) ascertain the frequency of MH 
assessment in RA pharmacotherapy trials; ii) quantify the efficacy of RA pharmacotherapy 
efficacy on MH outcomes; iii) explore the clinical and demographic factors related to MH 
outcomes. 
CENTRAL, PsychINFO, Web of Science, Medline, Embase and CINAHL were systematically 
searched from inception to March 2017 for randomised trials of disease-modifying anti-rheumatic 
drugs (DMARDs) in adult RA patients. The primary outcome was MH; self-reported physical 
health was extracted as a secondary outcome. Pairwise meta-analysis (PMA) created pooled 
effect sizes and 95%CIs for comparisons of all treatments versus comparators (active or 
placebo). Network meta-analysis (NMA) provided effect size estimates of targeted biologic 
DMARDs (bDMARDs) versus conventional synthetic DMARDs (csDMARDs) using indirect 
comparisons of different treatment modalities. 
71 eligible studies were identified. 57 studies were included in the PMA, representing 23,535 
patients. bDMARDs showed small effects on MH (standardised mean difference (SMD) versus 
csDMARDs = 0.19 to 0.30), and moderate effects on self-reported physical health (SMD versus 
csDMARDs = 0.46 to 0.50), with NMA determining no significant differences in effectiveness 
between bDMARD mode of action on either outcom .  
Effective pharmacotherapy alone is unlikely to substantially improve MH outcomes for most RA 
patients. Integrated MH care provided within routine clinical practice is essential to optimise 
mental and physical health outcomes.  
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INTRODUCTION 
Rheumatoid Arthritis (RA) is an autoimmune disease with a prevalence of 0.5-1.0% in adults. 
[1] RA causes swelling and pain of the joints (mainly hands, wrists and feet) reducing 
functional ability, which can substantially impact both physical and mental quality-of-life 
(QoL; [2]). Mental health (MH) disorders are highly prevalent; approximately 17% of RA 
patients have depressive disorder according to diagnostic interview [3] and 25.1% of 
rheumatology outpatients screen positive for anxiety disorder. [4] These estimates are 
substantially higher than for the general population, where depression prevalence estimates 
are typically around 5%. [5]  Poor MH is associated with numerous deleterious outcomes in 
RA; increased risk of mortality, [6] work disability, [7] worsened disease activity and physical 
function, [8–10] higher pain and [11] fatigue. [12]  
There is increasing evidence suggesting common inflammatory pathways between RA and 
depression. Specifically, inflammatory cytokines including tumour necrosis factor alpha 
(TNF-α) and interleukin-6 (IL-6) can be elevated in people with depressive disorder [13] and 
recent evidence suggests that therapies used in RA targeting TNF-α inhibitors may improve 
MH outcomes in depressed patients with high levels of inflammation, [14] and with chronic 
physical illness. [15]   
RA management has evolved in the last 25 years, with earlier diagnosis, and earlier, more 
aggressive treatment. [16] The “treat to target” framework emphasises the desired goal of 
reaching a state of remission, switching medications until this target has been achieved. 
[17,18] Initial treatment typically involves conventional synthetic disease-modifying anti-
rheumatic drugs (csDMARDs), usually methotrexate. In the UK, more expensive targeted 
biologic DMARDS (bDMARDs) are reserved for those with insufficient response to two 
csDMARDs. [19] For the purposes of this review, we use the term bDMARDs to encompass 
both targeted biologic and Janis kinase inhibitor (JAK) treatments. Whilst there has been 
evident improvements in radiographic outcomes and inflammation, impact on physical 
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function and QoL is less pronounced. [20,21] The limited impact on QoL is worrying given 
that psychosocial wellbeing and social function are of key importance to patients. [15] 
As low mood is highly prevalent in RA, [3]  and psychosocial wellbeing is important to 
patients, [22] it might be expected that MH is commonly assessed as an outcome in RA 
clinical trials. However, a 2009 systematic review found that MH outcomes were reported in 
4% of RA clinical studies, [23] increasing to 22% with a broader conceptualisation of mood 
including MH components of QoL using questionnaires such as the Medical Outcome 
Survey 36-item Short Form (SF36; [24]).   
The aim of this study was to systematically review the evidence around the efficacy of 
pharmacotherapy on improving MH outcomes in RA. The objectives were to: 1) identify the 
frequency with which MH outcomes are measured and reported in RA pharmacotherapy 
trials; 2) quantify the impact of bDMARDs on MH outcomes, comparing against self-reported 
physical health; and 3) investigate factors that may moderate RA pharmacological treatment 
efficacy for MH outcomes, such as treatment mode of action, patient demographic, and 
clinical characteristics.  
METHODS 
Identification of trials 
A protocol and data extraction form were developed in accordance with the Preferred 
Reporting Items for Systematic reviews and Meta-Analyses (PRISMA; [25]) statement 
(appendix 1). We searched the Cochrane Central Register of Controlled Trials (CENTRAL), 
PsychINFO, Medline, Embase, Web of Science and CINAHL from inception to March 2017. 
Search terms are available in the protocol, provided in appendix 2.  We also screened 
reference lists of reviews and ClinicalTrials.gov for trials still in progress. Titles were 
screened for relevance, followed by abstracts and full-texts to assess eligibility for inclusion. 
This screening procedure was conducted by reviewer FM, with reviewer ER following the 
same procedure for 10% (460/4604) of identified articles.  
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Selection criteria 
Types of patient 
Studies reporting data from adult patients aged >18 years with RA were included. Studies 
spanning several disease groups were only eligible if results from RA patients were reported 
separately. 
Study design and treatment types 
Randomised controlled trials (RCTs) of bDMARD pharmacological treatments for managing 
RA, including drugs in use in clinical practice at the time of study and new drugs under 
investigation, were eligible. Generic pain relief medication or alternative and complementary 
therapies such as acupuncture or collagen were excluded. Trials including active 
comparators (bDMARD vs. bDMARD), placebo control groups (bDMARD vs. placebo) or 
usual care control groups (bDMARD vs. csDMARD) were included, as were multi-arm trials 
(bDMARD vs. bDMARD vs. csDMARD). For cross-over trials, data were extracted from the 
first period only, to avoid potential carryover effects. Pragmatic trials, with patients shifting 
between treatment modalities and dosages according to treatment response were included 
in a narrative synthesis.   
Outcomes 
Our primary outcome of interest was MH, including both traditional depression and anxiety 
questionnaires and generic measures of QoL that include MH subscales. Data from these 
questionnaires were included if they were reported from MH subscales separately from 
overall quality-of-life or disability scores.  
Based on previous systematic review evidence, [23] we anticipated that the SF36 would be 
the most commonly-used questionnaire. If data were reported from more than one MH 
questionnaire, data from the SF36 were prioritised for inclusion in meta-analysis to reduce 
heterogeneity and aid interpretation. The SF36 has eight domains assessing various aspects 
of mental and physical well-being: physical function (PF); role physical (RP); global health 
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(GH); bodily pain (BP); vitality (V); social function (SF); role emotional (RE); and mental 
health (MH). [26] These domains can be combined to form two higher-order summary 
scores: Physical Component Summary (PCS); and Mental Component Summary (MCS). 
The PCS is formed by positively weighting the physical domains (PF, RP, GH, BP) and 
negatively weighting the mental domains (V, SF, RE, MH) and the MCS is calculated by 
positively weighting the mental domains and negatively weighting the physical domains. The 
PCS and MCS summary scores are inter-related, [27] yet provide an indicator of the impact 
of treatment on physical outcomes in comparison to mental outcomes, with higher scores 
indicating improved mental/physical QoL. PCS scores were considered secondary outcome 
data, to allow comparison between mental QoL and physical QoL outcomes following RA 
treatment. 
Data extraction 
Data were extracted from all eligible papers (N=71) by two reviewers (FM and ER) 
independently, to minimise human error in reporting results (appendix 3). In the case of 
incomplete reporting of data, we searched ClinicalTrials.gov, accessed company-specific 
registries, contacted authors directly, and made data requests to funding bodies as 
necessary.  
Risk of Bias 
A key assessment of the quality of the information provided by a trial is the potential for bias 
in the treatment effect estimate. Risk of bias of included trials was assessed by 2 reviewers 
(FM/ER) using the Cochrane tool. [28] This assessed random sequence generation, 
allocation concealment, participant, personnel and outcome assessor blinding, 
completeness of outcome data, and selective reporting. Where necessary, this data was 
obtained from “parent” primary outcome papers, where more detailed methodological 
information is included.  
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The quality of each outcome was assessed using the Grading of Recommendations 
Assessment, Development, and Evaluation (GRADE) system. A rating of high, moderate, 
low or very low was given to each outcome (MCS and PCS), based on assessment of risk of 
bias, inconsistency (between estimated effect sizes across studies and estimated I2 
heterogeneity), indirectness (applicability of study to the review aim), imprecision, and risk of 
publication bias (appendix 4).  
Statistical methods 
Standardised mean difference (SMD) effect sizes were calculated for each comparison using 
group means and standard deviations (SDs). The SMD indicates the size of the treatment 
effect relative to the observed variability in the outcome and can be interpreted as the 
between group difference in SD units; where an SMD of .5 indicates half a SD difference. A 
rule of thumb is that SMDs of .2, .5 and .8 are interpreted as small, medium, and large 
effects, respectively [29]. Where multiple doses of the same drug were tested, the most 
commonly used dosage, or dosage most reflecting clinical practice was included in the 
pooled meta-analysis. Where dose-finding studies of new drugs used a range of doses, the 
mean scores across dosages was taken. Endpoint means were prioritised, however mean 
change scores were included where endpoint scores were unavailable. If no mean scores or 
SDs were available after accessing ClinicalTrials.gov, or contacting authors and funding 
bodies, effect sizes were calculated using any available statistical estimates including t-
scores, 95% confidence intervals, and p-values. [30] Missing SD data were imputed by 
calculating the mean SD from data available from other studies using the same outcome, 
drug and dosage at the same time-point.  
The analysis involved random-effects pairwise meta-analysis (PMA), due to expected 
heterogeneity, including all studies regardless of comparator using Stata v14. Subgroup 
analyses compared active treatment separately with (no treatment) placebo and with 
csDMARD controls. Statistical heterogeneity in the between study treatment effects was 
assessed using I2 , with scores of 25%, 50% and 75% representing low, moderate and high 
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heterogeneity respectively. [31] The pooled treatment effect estimated may not be 
trustworthy when heterogeneity is high. Additionally, meta-regression was used to 
investigate between study differences in design and patient characteristics that might 
account for variability in between study treatment effects. Study sample size, age, proportion 
female, disease duration, baseline mood, baseline disease activity, follow-up time in weeks, 
rheumatoid factor (RF) status, recruitment year, and availability of data were entered as a 
bivariate exploration in studies of bDMARDs vs csDMARDs. A significant difference between 
analyses was established when confidence intervals did not overlap.  
Studies examining bDMARDs vs. csDMARDs were used in network meta-analysis (NMA) of 
targeted therapies by mode of action. NMA is an extension of traditional PMA to multiple 
treatment comparisons, which allows indirect comparisons to be made between different 
treatment types. [32] For example, if etanercept and abatacept have both been compared 
directly to MTX in different trials, the r lative effectiveness of etanercept versus abatacept 
can be estimated indirectly. This method also has the benefit of combining direct and indirect 
comparisons to provide a more precise (i.e. smaller standard errors) estimate of effect size. 
[32]   
Since the NMA grouped treatment by mode of action, it was necessary to exclude studies 
comparing bDMARDs with the same mode of action without a csDMARD or placebo control 
arm. Typically, such studies concerned a bDMARD biosimilar. Effect sizes were presented 
as pooled SMD and 95% CIs. Direct and indirect estimates of effect size were compared for 
bDMARD subcategories where direct comparisons were available, and comparison-adjusted 
funnel plots were created to indicate differences in effect sizes between small and large 
studies. Targeted treatments were ranked based on the estimated probability of each 
targeted treatment being most effective for MCS and PCS outcomes, which was estimated 
using surface under the cumulative ranking curve (SUCRA). SUCRAs combine the 
estimated probabilities (derived from the NMA) that each treatment is the first best, second 
best, and so on for all possible ranks (provided in web appendix 4). Higher SUCRA values 
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indicate greater likelihood of a given treatment being the most efficacious, such that where 
the SUCRA is one the treatment is certain to be the best, and where it is zero is certain to be 
the worst.  
RESULTS 
Search results and included participants 
A total of 71 studies, involving 34,796 participants, were identified (figure 1/table1). Full 
references for these studies are provided in appendix 6. The mean age of patients ranged 
from 47 to 57.5 years, 78.6% female, and the mean disease duration ranged between 0.1 
and 12.3 years.  The mean baseline MCS scores was 42.2 and the mean baseline DAS-28 
was 6.2. The studies considered 16 bDMARDs: anti-TNFs (adalimumab, certolizumab, 
etanercept, golimumab, infliximab); B-cell inhibitors (rituximab, SBI-087); T-cell inhibitors 
(abatacept); anti-IL6 (clazakizumab; sarilumab; sirukumab; tocilizumab) and Janus Kinase 
inhibitors (baricitinib, decernotinib, fostamitinib, tofacitinib).  
Objective 1: The frequency of MH outcome measurement 
Of the 71 eligible studies, with evidence of mood having been measured in either an 
abstract, methods, or as a list of outcomes on ClinicalTrials.gov, only 36 (50.7%) reported 
MH data in either publications, supplementary material, or open online data summary 
reports. Attempts were made to contact authors and funders of 32 of the remaining 35 
studies with insufficient information available (3 papers did not have contact information or 
funding information available); only 12 (36.4%) of these contact attempts resulted in receipt 
of the necessary data. Of the remaining 23 where no data were available, imputation of the 
missing information (e.g. SD of the outcome) was possible for 12 studies (allowing inclusion 
in the meta-analysis), 4 reported some data which were added to the narrative synthesis 
(appendix 7), and 7 were not able to be included in any outcome assessment. A total of 57 
papers were included in the PMA and 54 in the NMA. The three studies omitted from the 
NMA were head-to-head trials of targeted therapies in the same class. 
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>>TABLE 1<< 
>>FIGURE 1<< 
Objective 2: The impact of RA treatment on mental health 
Results of the PMA, sensitivity and subgroup analyses are shown in table 2. The total 
analysis involving 57 studies, with no exclusions and all comparators, revealed a statistically 
significant but modest effect of all treatments on mental HRQoL (MCS) (SMD=0.21). This 
indicates that, on average, bDMARDs were related to a treatment effect, compared to 
control treatments, of around one-fifth of a standard deviation, which is equivalent to around 
a two point difference in MCS units. In comparison, the impact of RA treatments on physical 
HRQoL (PCS) is somewhat larger (SMD= 0.41) and equivalent to a difference of around four 
points on the PCS scale. I2 values reflected moderate-high levels of heterogeneity for both 
PCS (I2=76.5) and MCS (I2=59.2) outcomes. This suggests that estimates may not be robust 
as an indicator of the population average effect; potentially due to moderating factors, such 
as differences in trial design. 
When limiting the analysis to no-treatment placebo controls, bDMARDs had a substantial 
benefit for PCS but not MCS outcomes (SMDs = .52 versus .27, respectively). Comparisons 
with csDMARD controls did not significantly alter the findings from the total analysis (SMDs 
= .47 versus .24, respectively). For both analyses, heterogeneity levels were reduced 
compared to the any comparator analysis but remained moderate (>40%) for both MCS and 
PCS outcomes. Subgroup analysis of unpublished data provided by authors and funders 
revealed little difference in impact of bDMARDs on MCS and PCS in comparison to 
background csDMARD control groups compared to all trials. 
csDMARDs (typically MTX) was a common comparator against which all bDMARDs had 
been assessed (see network of comparisons in appendix 5). NMA results for bDMARDs 
versus csDMARDs are shown in figure 3. These demonstrated consistently small effect sizes 
for MCS and moderate effects for PCS outcomes. All bDMARDs performed better than 
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csDMARDs for improving MCS and PCS outcomes, although there were no notable 
differences in outcomes between mode of bDMARD action. Effect sizes for MCS outcomes 
were typically 50% smaller than PCS effect sizes. Figure 2 shows the comparator-adjusted 
funnel plot for the NMA MCS outcome analysis, demonstrating no substantial publication 
bias.  
SUCRA rankings (figure 3) show that for MCS outcomes, out of the drugs considered in the 
analysis, biologics targeting anti-IL-6 have an 90% probability of being the most effective 
treatment for MCS outcome; abatacept has an 83% probability of most effectively improving 
PCS outcomes.  
>>FIGURE 2<< 
 
>>TABLE 2<< 
 
Objective 3: Variables associated with the impact of RA treatment on mood 
outcomes.  
The results of the meta-regression analyses, including studies to background csDMARD 
comparators, are provided in Table 3. These results show that sample size, age, proportion 
female, baseline levels of MH, disease activity, rheumatoid factor (RF) status, year of 
recruitment and availability of baseline data were not associated with variability in the 
treatment effect sizes in the PMA results for MCS or PCS outcomes. There was a small but 
significant positive association between disease duration and MCS outcomes and number of 
follow-up weeks and PCS outcomes. This indicates that every increased year of disease 
duration is associated with a 0.04 increase in MCS effect size (i.e. a reduction in treatment 
efficacy), and every increased week of follow-up time is associated with an increase of 0.01 
in PCS effect size.  
Page 11 of 68
John Wiley & Sons
Arthritis & Rheumatology
For Peer Review
12 
 
Risk of bias 
The GRADE assessment suggested that the MCS and PCS outcome PMA of bDMARD 
versus csDMARDs were of moderate quality. Whilst there was no serious indirectness, 
imprecision or publication bias, few studies were completely without risk of bias and there 
was moderate heterogeneity. A full summary of the risk of bias assessment is provided in 
appendix 4. 
>>FIGURE 3<< 
>>TABLE 3<< 
DISCUSSION 
Despite MH problems being highly prevalent, [3] predictive of worse disease outcomes and 
treatment response, [8,33] and being highlighted as a priority for outcome measurement by 
patients, [34,35] 74 (51.0%) of 145 otherwise eligible trials did not measure MH and were 
excluded from this systematic review. Of the 71 eligible studies indicating that MH had been 
measured, 35 (49.3%) did not report treatment effect estimates. The results of PMA of 57 
trials of targeted treatment show a relatively small but significant impact of bDMARDs on MH 
assessed by the SF36. The impact of targeted RA treatment on SF36-MCS was 
approximately half the effect seen in SF36-PCS. The largest effect size for MCS outcomes 
was 0.30, found for the anti-IL-6 versus csDMARD comparison; the lowest effect size was 
0.19, found in the Kinase inhibitors.  
To date, TNFα has been the primary focus of research investigating the inflammatory 
mechanisms involved in the presence of depressive symptomatology. Infliximab has been 
recently investigated as an anti-depressant in treatment-resistant depression, [14] and the 
impact of anti-TNF medications on depression outcomes in chronic physical conditions has 
been addressed in a recent systematic review and meta-analysis of six trials. [15] Building 
on this review, [15] we focused only on RA, but included broader conceptualisations of MH 
and more treatment types. By including treatments with varied modes of action, we hoped to 
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pinpoint the mechanism through which RA treatment may have benefits for MH. However, 
we failed to find any major variations between treatment modes of action. Whilst we found 
one of the largest effects on MH for treatments targeting IL-6, the smallest effect size was 
observed for anti-TNF treatments. Therefore, it remains largely unclear as to the extent to 
which improvements in MH are through bDMARDs directly impacting inflammatory 
pathways, or simply indirectly through the reduction in pain and disability. 
Meta-regression analysis identified a small but significant association between disease 
duration and MCS effect size, and the largest (although non-significant) R-squared value for 
comparing data which had been published online versus unpublished data which was 
requested from authors. Although we found no clear evidence of publication bias in our 
funnel plots, there may be a tendency for non-significant mental health outcomes to be 
omitted from published papers. [36] 
This review used reproducible and rigorous methods to collate and synthesize the data in 
this field. We included many trials, representing >20,000 patients, and study quality was 
relatively high. There are some restrictions which limit the interpretation of our results. We 
used broad inclusion criteria for the entry of studies into this review, preferring to use 
sensitivity and subgroup analyses and meta-regression to examine sources of statistical 
heterogeneity in the PMA, which was substantial. In addition to heterogeneity due to the 
different types of bDMARDs included, heterogeneity may also be explained by the 
comparator used, plus variability in disease duration and length of follow-up between 
studies. Another, source of heterogeneity may be that we did not restrict our focus to trials 
specifically recruiting patients with low mood at baseline. The overall mean MCS score at 
baseline was 42.2, with 20.8% of studies reporting a mean MCS score reaching below a 
threshold of 40, indicated as a threshold for possible mood disorder. [37] Most patients 
included in the studies may not have had mood disorder at baseline, restricting potential to 
find an ‘anti-depressant’ effect.  
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NMA methodologies are being more widely used in medical research, however there are 
limitations to the technique which need addressing. Firstly, it is important to highlight that, as 
treatment allocations have been randomised within (not between) trials, NMA can only 
provide observational evidence [38].  NMA assumes transitivity (whether any patient could 
be given any treatment in the network) and consistency (similar estimates obtained from 
direct and indirect comparisons). Our focus on bDMARDS, which are relatively recently 
developed, typically involve similar inclusion criteria, and generally are considered to be 
equally efficacious [39], limits the potential for violation of the transitivity assumption. 
Regarding the consistency assumption, examining loop specific heterogeneity we found no 
specific cause for concern.   
Despite not limiting our search strategy to the SF36, we identified the SF36 as the most 
commonly-used tool for measuring mental health, and data from this were prioritised to allow 
meaningful comparison across studies. Whilst this measure allows interesting comparison 
between mental and physical QoL outcomes, it is important to acknowledge that the SF36 
MCS captures a broader conceptualisation of mental health-related quality of life. This 
includes symptoms of depression and anxiety but also vitality/fatigue and impacts on social 
and emotional functioning. [24] Future research may benefit from identifying subgroups of 
patients who may be susceptible to experiencing MH benefits following RA treatments and 
understanding how these patients may differ from those who are more resistant to 
improvement. This may provide useful clinical information to anticipate treatment response, 
as improvement in MH in turn is likely to further impact physical symptom experiences [33]. 
This approach may also identify potentially useful intervention targets.  A focus on RA 
patients with symptoms of MH at baseline may provide insight into any benefits of RA 
treatment on a subgroup of people with both heightened inflammation and psychological 
disorder. 
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Conclusion 
Advances in RA treatment have resulted in significant improvements in specific outcomes: 
the delay of radiographic damage and reduction of inflammation and adverse events. [40] 
However this review demonstrates that relying on RA pharmacotherapy alone may not 
meaningfully improve MH outcomes. MH is treatable in patients with physical illness, [41,42] 
and the measurement and management of MH throughout the course of treatment as part of 
routine practice is recommended. [43] Our results suggest that MH in patients with RA must 
be addressed and are unlikely to resolve with effective RA pharmacological disease 
management alone. Providing integrated, dedicated MH care within routine practice is 
essential to achieve parity of esteem, valuing mental and physical health equally.  
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FIGURE LEGENDS 
Table 1: QD once per day. Q4w every 4 weeks. Eow every other week. Wk week. Q8w every 8 weeks. Biw twice 
a week. Bid twice a day. LOCF Last Observation Carried Forward. ITT Intention to Treat. MTX methotrexate 
Figure 1: Flow diagram of systematic literature search. 
Figure 2: Comparator-adjusted funnel-plot for MCS outcomes.   
Table 2: bDMARD targeted disease modifying anti-rheumatic drug. csDMARD conventional synthetic disease 
modifying anti-rheumatic drug. PCS = physical component summary scores (physical quality-of life). MCS = 
mental component summary scores (mental quality-of life). SMD Standardised Mean Difference. CI = Confidence 
Intervals. *placebo/csDMARD/steroid/bDMARD **Unpublished data supplied by author/funder. 
Figure 3: Estimated pooled treatment effects of biologics therapies on PCS and MCS outcomes. *Total bDAMRD 
versus csDMARDs pairwise analysis.  
Table 3:  MCS Mental Component Summary. PCS Physical Component Summary. DAS28 28-joint Disease 
Activity Score. RF Rheumatoid Factor. SMD Standardised Mean Difference. CI Confidence Interval. *Early RA 
defined as overall study mean disease duration <3 years 
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Figure 2: Comparator-adjusted funnel-plot for MCS outcomes.    
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Figure 3: Estimated pooled treatment effects of biologics therapies on PCS and MCS outcomes. *Total 
bDAMRD versus csDMARDs pairwise analysis.  
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Table 1. Study characteristics. 
Study ID Analysis 
Inclusion 
Interventions Year Patient N Female 
N (%) 
Mean 
Age, (SD) 
Mean 
disease 
duration 
(SD) 
Follow-
up 
(weeks) 
Missing 
data 
Mood 
measurement 
Baselin
e 
mood, 
mean 
(SD) 
ADACTA Meta-analysis Tocilizumab (8mg/kg 
q4w) vs adalimumab 
(40mg eow) 
2010-2011 325 262 
(80.6) 
53.4 
(12.7) 
6.8 24 LOCF SF36 - 
AIM Meta-analysis Placebo (+MTX) vs 
abatacept (10mg/kg 
q4w) 
 652 516 
(79.1) 
51.0 
(12.7) 
8.7 (7.2) 52 LOCF SF36 41.3 
(11.3) 
Alemao 2014 Meta-analysis MTX vs 
clazakizumab (25-
200mg q4w)        
MTX vs adalimumab 
(40mg eow) 
- 418 - - - 24 - SF36 - 
AMPLE Meta-analysis Abatacept 
(125mg/wk) vs 
adalimumab (40mg 
eow) 
- 646 529 
(81.9) 
51.2 
(12.7) 
1.8 (1.4) 104 Excluded SF36 43.5 
(11.5) 
APPEAL Meta-analysis DMARD+MTX   vs 
etanercept 
(50mg/wk) 
2007-2009 300 271 
(90.3) 
48.5 
(11.7) 
6.2 (7.9) 16 LOCF SF36   42.7   
ATTAIN Meta-analysis Placebo (+MTX)  vs 
abatacept (10mg/kg 
q4w) 
2002-2004 393 305 
(78.0) 
53.1 
(11.9) 
11.8 (8.7) 24 LOCF SF36 42.1 
(12.2) 
ATTEST Meta-analysis Placebo (+MTX) vs 
abatacept (10mg/kg)  
Placebo vs infliximab 
(3mg/kg) 
- 431 362 
(84.0) 
49.2 
(12.0) 
 28 LOCF SF36 - 
ATTRACT Narrative 
Synthesis 
Placebo (+MTX) vs 
infliximab (3mg/kg 
q8w-10mg/kg q4w 
1997-1998 428 332 
(78.0) 
54 10.6 (8.4) 102 - SF36 Median 
= 48.1 
AVERT Meta-analysis MTX vs abatacept 
(125mg/wk) 
- 511 273 
(77.8) 
47.0 
(12.6) 
0.6 (0.5) 24, 52 Imputation SF36 41.3 
(11.2) 
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BEST Narrative 
Synthesis 
Sequential 
monotherapy vs 
step-up combination 
therapy vs initial 
combination therapy 
+ prednisolone vs 
initial combination 
therapy + infliximab 
2000-2002 508 343 
(67.5) 
54.4 
(13.8) 
Median = 
0.5 
12, 24, 
52, 104 
ITT SF36 47.3 
Burmester 2013  Excluded Placebo (+MTX)  vs 
mavrilimumab 
(100mg eow) 
- 139 - - - 4, 12 - SF36 - 
CERTAIN Meta-analysis Placebo (+MTX) vs 
certolizumab 
(200mg) 
2008-2010 194 156 
(80.4) 
53.8 
(12.2) 
4.6 (3.4) 24 LOCF SF36 43.2 
(10.7) 
Choy 2012 Meta-analysis Placebo (+MTX)  vs 
certolizumab 
(400mg) 
2002-2004 247 171 
(69.2) 
54.3 
(12.0) 
9.7 (7.7) 24 LOCF SF36 45.7 
(12.3) 
COMET Meta-analysis MTX (7.5mg-
50mg/wk) vs 
etanercept 
(50mg/wk) 
2004-2006 542 387 
(73.0) 
51.4 
(13.8) 
0.8 (0.5) 52 LOCF SF36, HADS SF36: 
42.2 
(12.0) 
HADS 
(dep): 
6.8 
(4.1)   
HADS 
(anx): 
7.5 
(4.4) 
CONCERTO Narrative 
Synthesis 
MTX 
(2.5mg/5mg/10mg/20
mg) vs adalimumab 
(40mg eow) 
2010-2012 395 300 
(75.9) 
51.9 
(13.4) 
0.3 (0.4) 26 LOCF SF36 - 
Damjanov 2016 Meta-analysis SBI-087 (200mg) + 
MTX vs placebo 
(+MTX)   
- 209 164 
(78.5) 
54.7 
(12.2) 
8.5 (7.8) 16, 24 LOCF SF36 - 
DANCER Meta-analysis Placebo (+MTX)   vs 
rituximab (2x500mg)     
Placebo (+MTX)   vs 
rituximab 
(2x1000mg) 
- 367 287 
(78.2) 
51.4 
(11.6) 
10.7 (8.2) 24 Excluded SF36 41.4 
(12.0) 
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Durez 2004 Meta-analysis Infliximab (3mg/kg) 
(+MTX)  vs 
methylprednisolone 
(1g) (+MTX)   
- 27 23 
(85.2) 
Median 
=42.0 
Median 
=11.0 
14 - SF36 48.5 
Emery 2006 Meta-analysis Placebo (+MTX)  vs 
abatacept (10mg/kg)   
Placebo (+MTX)  vs 
abatacept (2mg/kg) 
- 339 230 
(68.0) 
55 9.4 (8.7) 52 LOCF SF36 43.8 
(12.7) 
FAST4WARD Meta-analysis Placebo vs 
certolizumab 
(400mg) 
2003-2004 220 184 
(83.6) 
53.8 
(12.2) 
9.6 (8.9) 24 Imputation SF36 44.7 
(11.5) 
FUNCTION Meta-analysis Placebo (+MTX) vs 
tocilizumab 
(4mg/kg)+MTX 
Placebo (+MTX) vs 
tocilizumab 
(8mg/kg)+MTX   
Placebo  (+MTX) vs 
tocilizumab (8mg/kg) 
- 1157 904 
(78.1) 
50.1 
(13.5) 
0.5 (0.5) 24, 52 Excluded SF36 - 
Genovese 2004  Excluded Etanercept (25mg 
biw) (+MTX) vs 
etanercept (25mg 
biw) + anakinra 
(100mg qd) (+MTX)                                     
Etanercept (25mg 
biw) (+MTX)  vs 
etanercept (25mg 
qw) + anakinra 
(100mg qd) (+MTX) 
- 242 187 
(77.3) 
54.6 
(12.8) 
9.9 (9.8) 24 ITT SF36 46.4 
(11.7) 
GO-FORWARD Meta-analysis Placebo (+MTX) vs 
golimumab (100mg)      
Placebo (+MTX) vs 
golimumab (50mg)          
Placebo (+MTX) vs 
golimumab 
(100mg)+MTX 
2005-2007 444 358 
(80.6) 
50.4 
(11.3) 
8.3 (8.0) 24 ITT SF36 43.8 
(11.0) 
GO-FURTHER Meta-analysis Placebo (+MTX) vs 
golimumab (2mg/kg) 
2009-2011 592 483 
(81.6) 
51.8 
(12.1) 
7.0 (7.1) 24 LOCF SF36 37.6 
(11.3) 
HERA Meta-analysis HD203 (25mg biw) 
vs etanercept (25mg 
2010-2012 294 202 
(68.7) 
51.2 
(12.2) 
7.7 (7.4) 24, 48 LOCF SF36 39.8 
(11.6) 
Page 26 of 68
John Wiley & Sons
Arthritis & Rheumatology
For Peer Review
biw) (+MTX) 
HIKARI Meta-analysis Placebo (+MTX) vs 
certolizumab 
(200mg) 
2008-2010 230 171 
(74.3) 
55.7 
(10.0) 
5.6 (4.2) 12, 24 LOCF SF36 44.8 
(12.9) 
HIT HARD Meta-analysis Placebo (+MTX) vs 
adalimumab (40mg 
eow) 
2007-2010 172 118 
(68.6) 
49.9 
(13.2) 
0.1 (0.7) 24, 48 MI SF36 46.0 
(10.1) 
IMAGE Meta-analysis Placebo (+MTX) vs 
rituximab (2x500mg)     
Placebo (+MTX) vs 
rituximab 
(2x1000mg) 
2006-2007 748 607 
(81.1) 
48.0 
(13.1) 
0.9 (1.2) 52 LOCF SF36 36.7 
(12.2) 
J-RAPID Meta-analysis Placebo (+MTX) vs 
certolizumab 
(400mg)            
Placebo (+MTX) vs 
certolizumab 
(200mg)             
Placebo (+MTX) vs 
certolizumab 
(100mg) 
2008-2010 316 262 
(82.9) 
53.1 
(10.9) 
5.9 (4.1) 24 LOCF SF36 46.6 
(11.7) 
Keystone 2004 Narrative 
Synthesis 
Placebo (+MTX) vs 
adalimumab (40mg 
biw)                
Placebo (+MTX) vs 
adalimumab (20mg 
biw) 
- 619 464 
(75.0) 
56.5 
(12.0) 
11.0 (9.1) 12, 24, 
52 
ITT SF36 - 
Kim 2013 Excluded Placebo (+MTX) vs 
infliximab (3mg/kg) 
2005-2006 143 128 
(89.5) 
50.4 
(10.8) 
Median 
=8.6 
30 ITT SF36 - 
Kremer 2003 Narrative 
Synthesis 
Placebo (+MTX) vs 
abatacept (2mg/kg 
q4w)                 
Placebo (+MTX) vs 
abatacept (10mg/kg 
q4w) 
2000-2001 339 231 
(68.1) 
55 9.4 (8.7) 24 LOCF SF36 43.2 
(10.8) 
Kremer 2014 Excluded Placebo (+MTX) vs 
mavrilimumab (30-
100mg eow) 
- 326 282 
(86.5) 
51.8 
(11.1) 
- 12, 24 ITT SF36 - 
Li 2016 Meta-analysis Placebo (+MTX) vs - 264 214 47.2 7.8 (7.2) 24 LOCF SF36 39.6 
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golimumab (50mg 
q4wks) 
(81.1) (11.8) (11.1) 
Machado 2014 Meta-analysis DMARD+MTX 
(7.5mg-25mg/wk) vs 
etanercept 
(50mg/wk)+MTX 
(7.5mg-25mg/wk) 
2009-2012 423 376 
(88.8) 
48.5 
(11.7) 
8.5 (7.3) 24 LOCF SF36 SF36: 
40.0 
(10.7)  
Manders 2015 Excluded Anti-TNF vs 
abatacept (10mg/kg 
q4w)                     
Anti-TNF vs 
rituximab (1000mg 
eow) 
2009-2012 144 104 
(74.8) 
56.3 
(11.2) 
Median = 
6.3 
24, 52 ITT SF36 - 
Mathias 2000 Meta-analysis Placebo vs 
etanercept (25mg 
biw)                
Placebo vs 
etanercept (10mg 
biw) 
- 234 182 
(77.9) 
52.3 12 2, 12, 24 LOCF SF36 41.7 
Mease 2012 Meta-analysis Placebo (+MTX) vs 
clazakizumab (80-
320mg) 
2008-2009 127 - 52.5 
(11.3) 
7.0 (6.0) 16 ITT SF36 34.5 
(11.9) 
MUSICA Narrative 
Synthesis 
MTX 
(7.5mg/wk)+adalimu
mab (40mg eow) vs 
MTX 
(20mg/wk)+adalimu
mab (40mg eow) 
- 309 - 54.8 - 24 LOCF SF36 - 
OPERA Meta-analysis Placebo (+MTX) vs 
adalimumab (40mg 
eow) 
2007-2009 180 119 
(66.1) 
55.2 0.2 52 LOCF SF36 46.9 
OPTION Meta-analysis Placebo (+MTX) vs 
tocilizumab (4mg/kg) 
Placebo (+MTX) vs 
tocilizumab (8mg/kg) 
2005-2006 623 510 
(81.9) 
50.9 
(12.2) 
7.6 (7.3) 24 Excluded SF36 40.0 
(11.1) 
ORAL Meta-analysis Placebo (+MTX) vs 
tofacitinib (5/10mg 
bid) 
2009-2011 399 335 
(84.0) 
55.0 
(11.4) 
12.3 24 ITT SF36 42.5 
(12.9) 
ORAL-SCAN Meta-analysis Placebo (+MTX) vs 
tofacitinib (5/10mg 
bid) 
2009-2011 797 679 
(85.2) 
52.8 
(11.6) 
9.1 4, 12, 
24, 52 
Excluded SF36 42.1 
(11.6) 
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ORAL-
STANDARD 
Meta-analysis Placebo (+MTX) vs 
tofacitinib (5/10mg 
bid)                    
Placebo (+MTX) vs 
adalimumab (40mg 
eow) 
2009-2011 717 586 
(81.7) 
53.2 
(12.6) 
7.8 24 Excluded SF36 41.0 
(11.3) 
ORAL-START  Meta-analysis MTX (10mg-
20mg/wk) vs 
tofacitinib (5/10mg 
bid) 
2010-2013 956 758 
(79.3) 
49.5 3 52, 104 Excluded SF36 - 
ORBIT Meta-analysis MTX + rituximab 
(2x500mg) vs MTX + 
anti-TNF 
(adalimumab 40mg 
eow or etanercept 
50mg pw) 
2009-2013 295 213 
(72.2) 
57.0 
(10.0) 
7.4 (7.3) 52 ITT HADS - 
PLANETRA Meta-analysis Infliximab (3mg/kg) 
vs biosimilar (CT-
P13 3mg/kg) 
- 506 501 
(82.7) 
Median = 
50 Range 
18-75 
- 14, 30, 
54 
LOCF SF36 37.6 
(10.9) 
PREMIER Meta-analysis MTX (20mg/wk) vs 
adalimumab (40mg 
eow) vs adalimumb 
(40mg eow) + MTX 
(20mg/wk) 
- 799 595 
(74.5) 
52.0 
(13.5) 
0.7 (0.8) 12, 26, 
52, 76, 
104 
- SF36 43.4 
(12.3) 
PRIZE Meta-analysis Placebo (+MTX) vs 
MTX (10-25mg/wk) 
vs etanercept (25mg) 
+MTX 
2009-2012 193 125 
(64.8) 
49.4 
(14.4) 
0.3 (0.2) 39 LOCF SF36 43.5 
(10.8) 
RA-BEACON Meta-analysis Placebo (+DMARD) 
vs MTX + baricitinib 
(2mg or 4mg daily) 
2013-2014 527 431 
(81.8) 
55.7 
(11.0) 
14.0 (9.0) 24 ITT SF36 - 
RA-BEAM  Meta-analysis Placebo (+MTX) vs 
baricitinib (4mg QD) 
vs adalimumab 
(40mg q2w) 
2012-2014 1305 1008 
(77.2) 
53.3 (5.3) 10.0 (9.0) 24 LOCF SF36 - 
RADIATE Meta-analysis Placebo (+MTX) vs 
tocilizumab 
(4mg/kg)+MTX 
Placebo (+MTX) vs 
tocilizumab 
(8mg/kg)+MTX 
- 499 398 
(79.8) 
52.7 
(12.8) 
11.7 (9.0) 24 Excluded SF36 41.1 
(11.9) 
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RA-MOBILITY  Meta-analysis Placebo (+MTX) vs 
sarilumab (150mg 
q2w)                   
Placebo (+MTX) vs 
sarilumab (200mg 
q2w) 
- 1197 982 
(82.0) 
50.6 
(11.6) 
9.1 52 ITT SF36 38.9 
(11.6) 
RAPID1 Meta-analysis Placebo (+MTX) vs 
certolizumab 
(400mg)            
Placebo (+MTX) vs 
certolizumab 
(200mg) 
2005-2006 982 817 
(83.2) 
52.0 
(11.5) 
6.2 (4.3) 12, 24, 
52 
LOCF SF36 39.3 
(11.2) 
RAPID2 Meta-analysis Placebo (+MTX) vs 
certolizumab 
(400mg)            
Placebo (+MTX) vs 
certolizumab 
(200mg) 
2005-2006 619 505 
(81.6) 
51.9 
(11.6) 
6.1 (4.1) 24 LOCF SF36 39.4 
(11.1) 
REFLEX Meta-analysis Placebo (+MTX) vs 
rituximab 
(2x1000mg) 
- 520 420 
(80.8) 
52.5 
(12.4) 
11.9 (8.0) 24 LOCF SF36 39.9 
(11.4) 
SERENE Meta-analysis Placebo (+MTX) vs 
rituximab (2x500mg)     
Placebo (+MTX) vs 
rituximab 
(2x1000mg) 
- 511 418 
(81.8) 
51.8 
(12.7) 
7.1 (7.3) 24 Excluded SF36 41.2 
(11.9) 
SIRROUND-D Meta-analysis Placebo (+MTX) vs 
sirukumab (50mg 
q2w or 100mg q4w) 
2012-2016 1670 - - - 24 ITT SF36 - 
SIRROUND-T Meta-analysis Placebo (+MTX) vs 
sirukumab (50mg 
q2w or 100mg q4w) 
2012-2016 878 712 
(81.0) 
55.4 
(12.2) 
12.5 (8.9) 24 ITT SF36 - 
Smolen 2012 Meta-analysis Placebo (+MTX) vs 
baricitinib (1mg-8mg) 
- 301 - - - 12 - SF36 - 
Smolen 2014a Meta-analysis Placebo (+MTX)  vs 
sirukumab (100mg 
eow) 
2008-2011 36 25 
(69.4) 
48.2 (7.0) 7.4 (6.8) 12 LOCF SF36 37.4 
(11.3) 
Smolen 2014b Meta-analysis Placebo (+MTX) vs 
sirukumab (25-
200mg q4w) 
2008-2011 151 133 
(88.1) 
52.7 
(11.3) 
10.0 (7.5) 12 LOCF SF36 37.2 
(11.3) 
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St Clair 2004 Excluded Placebo (+MTX)  vs 
infliximab (3mg/kg)                
Placebo (+MTX) vs 
infliximab (6mg/kg) 
2000-2002 1004 713 
(71.0) 
50.3 
(12.7) 
0.9 (0.7) 54 LOCF SF36 - 
START Excluded Placebo (+MTX) vs 
infliximab (10mg/kg)   
Placebo (+MTX) vs 
infliximab (3mg/kg) 
2001-2003 1084 871 
(80.4) 
52.3 7.5 22 LOCF SF36 45.1 
Strand 2011 Meta-analysis Placebo (+MTX) vs 
tofacitinib (5/10mg 
bid) 
- 792 - - - 24 Excluded SF36 41.4 
(11.8) 
Strand 2012 Narrative 
Synthesis 
Placebo vs 
secukinumab  (25-
300mg q4w) 
- 237 - - - 2, 4, 8, 
12, 16 
- SF36 - 
Strand 2013 Meta-analysis Placebo vs 
decernotinib   (25-
150mg bid) 
- 204 - 56.2 (9.9) 7.7 12 Imputation SF36 39.0 
(11.7) 
TACIT Meta-analysis cDMARD strategy vs 
tumour necrosis 
factor inhibitor 
strategy  
2008-2010 214 144 
(67.3) 
57.5 
(12.0) 
Median = 
5.2 Range 
= 1.6-13.4 
52 MI SF36 42.0 
(12.0) 
TASKi-2 Meta-analysis Placebo (+MTX) vs 
fostamatinib (100mg 
bid)                        
Placebo (+MTX) vs 
fostamatinib 
(150mg/day) 
- 457 390 
(85.3) 
52.5 
(12.8) 
9.2 (8.7) 24 ITT SF36 40.3 
(11.6) 
TOWARD Meta-analysis Placebo (+MTX) vs 
tocilizumab (8mg/kg) 
2005-2007 1220 997 
(81.7) 
53.5 
(13.0) 
9.8 (9.0) 24 ITT SF36 - 
Westhovens 
2009 
Meta-analysis Placebo (+MTX) vs 
abatacept (10mg/kg 
q4w) 
- 509 395 
(77.6) 
49.9 
(12.7) 
0.5 (0.6) 52 LOCF SF36 - 
QD once per day. Q4w every 4 weeks. Eow every other week. Wk week. Q8w every 8 weeks. Biw twice a week. Bid twice a day. LOCF Last Observation Carried 
Forward. ITT Intention to Treat. MTX methotrexate 
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Table 2. Pairwise meta-analysis results with sensitivity and subgroup analysis. 
Analysis Outcome Number of 
studies 
Number of 
comparisons 
Number of 
participants 
SMD (95% CI) p-value I2 statistic 
(%) 
bDMARD vs any comparator* SF36 MCS 57 67 23,535 0.21 (0.17, 0.25) <0.001 59.2 
 SF36 PCS 55 65 23,108 0.41 (0.35, 0.47) <0.001 76.5 
bDMARD vs no-treatment 
placebo 
SF36 MCS 7 7 2,700 0.27 (0.16, 0.38) <0.001 41.6 
 SF36 PCS 6 6 2,542 0.52 (0.40, 0.64) <0.001 41.3 
bDMARD vs csDMARD SF36 MCS 44 47 16,678 0.24 (0.19, 0.29) <0.001 52.9 
 SF36 PCS 44 47 16,678 0.47 (0.42, 0.52) <0.001 57.4 
bDMARD vs csDMARD 
(unpublished)** 
SF36 MCS 10 12 3,352 0.22 (0.12, 0.32) <0.001 46.2 
 SF36 PCS 10 12 3,352 0.45 (0.35, 0.55) <0.001 38.4 
bDMARD targeted disease modifying anti-rheumatic drug. csDMARD conventional synthetic disease modifying anti-rheumatic drug. PCS = physical component summary 
scores (physical quality-of life). MCS = mental component summary scores (mental quality-of life). SMD Standardised Mean Difference. CI = Confidence Intervals. 
*placebo/csDMARD/steroid/bDMARD **Unpublished data supplied by author/funde .  
 
 
 
 
 
 
Page 32 of 68
John Wiley & Sons
Arthritis & Rheumatology
For Peer Review
Table 3. Meta-regression of moderators of the impact of RA treatment on MCS and PCS outcomes. 
MCS Comparison N Study N Participant N SMD (95%CI) p value  I2 Statistic (%) 
Comparison analysis:                                  
Total versus background DMARD control 
44 47 16,678 0.24 (0.19, 0.29) <0.0001 52.9 
Covariates Beta SE Lower CI Upper CI  p value R-Squared (%) 
Age (continuous) 0.01 0.01 -0.01 0.03 0.244 0.31 
Proportion female (continuous) 0.01 0.01 -0.01 0.03 0.683 -0.06 
Disease duration (years, continuous) 0.04 0.02 0.00 0.07 0.038 2.83 
Early RA (versus established RA)* -0.28 0.16 -0.61 0.04 0.084 1.68 
MCS at baseline (continuous) -0.03 0.03 -0.08 0.03 0.324 0.04 
DAS28 at baseline (continuous) 0.04 0.16 -0.28 0.35 0.806 -0.86 
Follow-up time (weeks, continuous) 0.01 0.00 -0.00 0.01 0.056 1.94 
Percentage RF positive 0.00 0.01 -0.02 0.02 0.872 -0.89 
Year of recruitment start 0.05 0.04 -0.03 0.12 0.213 0.86 
Unpublished (versus published) 0.11 0.17 -0.23 0.46 0.519 4.12 
PCS Comparison N Study N Participant N SMD (95%CI) p value  I2 Statistic (%) 
Comparison analysis: 
Total versus background DMARD control 
44 47 16,678 0.47 (0.42, 0.52) <0.0001 57.4 
Covariates Beta SE Lower CI Upper CI  p value R-Squared (%) 
Age (continuous) 0.01 0.01 -0.01 0.03 0.356 -0.09 
Proportion female (continuous) 0.00 0.02 -0.03 0.03 0.986 -0.82 
Disease duration (years, continuous) 0.04 0.02 -0.00 0.09 0.066 2.22 
Early RA (versus established RA)* -0.22 0.20 -0.61 0.16 0.250 0.34 
MCS at baseline (continuous) -0.03 0.03 -0.09 0.04 0.373 -0.12 
DAS28 at baseline (continuous) 0.06 0.19 -0.31 0.44 0.735 -0.84 
Follow-up time (weeks, continuous) 0.01 0.00 -0.00 0.01 0.045 2.27 
Percentage RF positive -0.01 0.01 -0.03 0.02 0.535 -0.73 
Year of recruitment start 0.07 0.05 -0.02 0.16 0.129 1.82 
Unpublished data (versus published) 0.11 0.22 -0.32 0.54 0.628 6.72 
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MCS Mental Component Summary. PCS Physical Component Summary. DAS28 28-joint Disease Activity Score. RF Rheumatoid Factor. SMD Standardised Mean Difference. CI 
Confidence Interval. *Early RA defined as overall study mean disease duration <3 years 
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Web-Appendix: The impact of targeted Rheumatoid 
Arthritis pharmacological treatment on mental health: A 
systematic review and network meta-analysis. 
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Web-Appendix 1: PRISMA checklist 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): 
e1000097. doi:10.1371/journal.pmed1000097  
 
Section/topic  # Checklist item  
Reported 
on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  1 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and 
implications of key findings; systematic review registration number.  
2 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  3-4 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, 
outcomes, and study design (PICOS).  
4 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
4 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of followup) and report characteristics (e.g., years considered, 
language, publication status) used as criteria for eligibility, giving rationale.  
5-6 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify 
additional studies) in the search and date last searched.  
4 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be 
repeated.  
4 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, 
included in the metaanalysis).  
5-7 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes 
for obtaining and confirming data from investigators.  
6 
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Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and 
simplifications made.  
6 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was 
done at the study or outcome level), and how this information is to be used in any data synthesis.  
6-7 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  7-8 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency 
(e.g., I
2
) for each metaanalysis.  
7-8 
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective 
reporting within studies).  
7-8 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating 
which were prespecified.  
7-8 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at 
each stage, ideally with a flow diagram.  
8 (figure 
1) 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and 
provide the citations.  
9-16 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  20 
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
18-19 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  18-19 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  20 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).  21 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to 
key groups (e.g., healthcare providers, users, and policy makers).  
22 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).  
23-24 
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Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  24 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the 
systematic review.  
25 
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Web-Appendix 2: Study protocol 
 
Background 
Rheumatoid Arthritis (RA) has a large impact on health-related quality-of-life (HRQoL) [1]. 
Treatment of RA typically has two key aims: 1) the reduction of symptoms to improve quality-
of-life for patients; and 2) to prevent further joint damage and preserve existing physical 
function [2]. Therapy for RA typically involves treatment with conventional synthetic Disease 
Modifying Anti-Rheumatic Drugs (csDMARD). Non-response to first-line csDMARD 
Methotrexate (MTX) leads to the addition of more csDMARD treatments in addition to MTX. 
Failure to respond to combination csDMARD therapy can lead to the addition of targeted 
biologic therapies, which inhibit immune system components which are pivotal in regulating 
inflammation (tDMARD). There is also a recent focus on small molecule therapies, which 
target cellular structures and intracellular signalling proteins.  There is currently substantial 
evidence demonstrating the impact of RA treatment on physical health outcomes, however 
there has been relatively little attention paid to the mental HRQoL outcomes achieved 
through RA therapy. Mental health is an outcome prioritised by patients but rarely measured 
in RA clinical trials [3,4]   
The aims of this review are to: a) review the frequency ; b) provide meta-analysed pooled 
mean scores for mood outcomes for each treatment type; and c) examine the impact of 
study and patient characteristics on pooled mean scores via sensitivity and subgroup 
analysis.  
Objectives 
The aims of this systematic review are to assess: a) the frequency of reporting mental health 
outcomes in targeted treatment trials in RA; b) evaluate the impact of RA therapies on 
mental health outcomes; and c) investigate the study-level variables that moderate the 
efficacy of pharmacological treatments. 
Primary Outcome: Mental health-related quality of life (HRQoL) 
Secondary Outcome: Physical HRQoL 
Criteria for inclusion in the review 
(i) Types of studies  
This review will include only Randomised Controlled Trials, with active or placebo 
comparators.  
(ii) Types of participants  
Participants eligible for inclusion will be adults suffering from clinically verified RA.  
(iii) Treatment types 
Any targeted pharmacological treatment (in development or current use) will be included. 
Generic pain relief, complementary and alternative therapies will be excluded.  
 
(iv) Outcome measurement 
Mood must be measured by any tool which includes psychological constructs such as the 
AIMS, SF-36 or depression/anxiety screening tools.  
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Exclusion Criteria 
Papers shall be excluded from the analysis if they meet any of the following criteria: 
1. Non-RCT design 
2. Are duplicates, using the same patient data in multiple publications.  
 
Strategy for identification of studies 
A systematic electronic search of Medline, Embase, PsycINFO, Web of Science and 
CENTRAL will be conducted, and data extracted using forms developed in accordance with 
the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) 
statement.  
The search strategy will use the following search terms: 
((Clinical trial or Randomized controlled trial or Randomization or Single blind procedure or 
Double blind procedure or Crossover procedure or Placebo or Randomi?ed controlled trial$ 
or Rct or Random allocation or Randomly allocated or Allocated randomly or (allocated adj2 
random) or Single blind$ or Double blind$ or ((treble or triple) adj blind$) or Placebo$ or 
Prospective study) not (Case study or Case report or (Abstract report or letter))).af. 
AND 
(rheumatoid arthritis or RA).ab. 
AND 
(depress* or depress* disorder$ or affective disorder$ or mood disorder$ or adjustment 
disorder$ or affective symptom* or dysthymi* or anxiety disorder$ or GAD or panic disorder$ 
or mood or mental health or quality-of-life or QoL or HRQoL or SF-36 or Medical Outcomes 
Study).af. 
Studies pertaining to RCTs will be identified via the RCT search filter provided by SIGN 
(http://www.sign.ac.uk/methodology/filters.html#random) 
Data collection and analysis 
Selection of Studies and Data Extraction  
Potentially eligible studies generated from the literature search will be assessed according to 
the previously mentioned inclusion criteria and data extraction forms. The titles and abstracts 
of the papers will initially be scanned, and if it remains unclear if the study meets the 
eligibility criteria, the full document will be accessed. This will be done by two independent 
researchers.  
Data Analysis  
Continuous end-point data will be assessed by calculation of standardized mean differences 
(SMDs) using available mean values and their standard deviations, together with 95% CIs 
using random-effects pairwise meta-analysis (PMA). Alternatively, mean scores and SDs 
post treatment can be used if reported, or imputed from confidence intervals, t-scores and p-
values. Data will be pooled in Stata using random-effects meta-analysis and I2 to assess 
heterogeneity [5]. Network meta-analysis (NMA) will be used to combine direct and indirect 
comparisons, providing SMD, 95%CIs and p-values. This will provide comparison of effect 
sizes between targeted DMARDs by mode of action.  A significant difference between 
analyses stages will be considered if confidence intervals do not overlap.   
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Investigation of Heterogeneity 
Sensitivity analyses will exclude studies not using the SF36 to measure mental health 
outcomes. Subgroup analyses will investigate the different effect sizes obtained with 
different control/comparison groups and by the availability of data. Meta-regression will 
evaluate the study and patient variables which might be assocated with effect size: baseline 
mood, baseline disease activity, RF status, recruitment year and data availability).  
Risk of Bias 
Two independent researchers will assess randomisation processes, blinding, analyses 
appropriateness and will discuss disagreements to reach consensus. The generation of 
allocation sequence and concealment of allocation will be considered acceptable if study 
investigators are unaware of upcoming allocations. Random sequence generation is 
considered adequate if explicit reference is made to a centralised system including random 
number generator, interactive voice response system or sealed envelopes. Studies are 
considered adequately blinded if participants investigators involved in administering drugs 
and collecting outcomes cannot distinguish between placebo and active drugs. Studies will 
be considered inadequate if results included in the current analysis (mental HRQoL) are 
provided for completers only, instead of all randomised participants. All studies mentioning 
measuring HRQoL (or other outcomes) in a methods section but not reporting the findings of 
these outcomes in a published paper, conference abstract, or online repository will be 
considered at high risk of bias for selective outcome reporting.  
Funding 
This work is being undertaken as part of PhD investigating mental health in Rheumatoid 
Arthritis. Salary support for this independent research, is provided by the National Institute 
for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley 
NHS Foundation Trust and King’s College London. The views expressed are those of the 
author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.  
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Web-Appendix 3: Data Extraction form 
 
Title of paper: 
Authors: 
Name of reviewer:       
Date of data extraction:  
Trial Name:  
Eligibility Assessment: 
 
 
ELIGIBLE? Y/N 
Study details 
 
Publication:  Full report  Abstract  Thesis  Unpublished 
Funding:  Non-commercial   Commercial   Not stated 
Do any authors have industrial affiliation?  Yes  No   Unclear 
Country of origin: 
Original language of any study papers that were translated: 
Statement of ethical approval from appropriate authority:  Yes  No  Unclear 
Is the study reported according to the CONSORT agreement?  Yes  No  Unclear 
 
 
 
 
Diagnosis  
Design  
Treatment Type  
Treatment Category  
Control  
Mental Health Measurement  
Data Reported  
Aim(s) of the study: 
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Participants 
Start date of recruitment period (MM/YY):  
End date (MM/YY):  
How many patients per treatment arm?  
Treatment type: 
R DMARD 
R Biological 
R Anti-TNF 
R JAK inhibitor 
R NSAID 
R Corticosteroids 
R Other 
Targeted treatment type: 
Anti-TNFs 
 Adalimumab  Certolizumab  Etanercept  Golumimumab  Infliximab   
 Other  
 
B-cell inhibitor 
 Rituximab  Other  
Anti-IL6 
 Tocilizumab  Other  
T-cell inhibitor  
 Abatacept  Other  
JAK inhibitor 
R Tofacitinib R Other   
Other 
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How has mood been measured? 
Which SF-36 Outcomes have been measured? 
 PCS  MCS  PF  BP  RF GH  VT  SF  RE  MH 
Were the eligibility criteria specified?   Yes    No   
What are the eligibility criteria? 
 
 
 
 
 
 
 
Study setting 
Centres:  Single-centre   Multi-centre  Not stated 
Type(s) of centre:  Inpatient hospital  Inpatient hospice  Outpatient / clinic 
 Primary care    Other community   Other than listed here 
Intervention and outcome measure(s) 
Study design 
Randomized Controlled Trial?  Yes  No 
Control Arm:  No-treatment placebo  Conventional DMARD   Had-to-head 
Risk of Bias 
• Allocation Concealment 
 Central randomisation    Coded containers   
 Sealed envelopes    Other concealment (please state): 
 Not specified 
  
Dosage: 
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Was allocation adequately concealed?   Yes  No  Unclear 
 
• Sequence Generation 
 Random number table  Computer generated  Tossing or shuffling 
 Other (please state)  No adequate method reported 
Was the allocation sequence adequately generated?  Yes  No  Unclear 
 
• Blinding 
Was the patient blinded?    Yes   No  Don’t know 
Was the outcome assessor blinded?   Yes   No  Don’t know 
Was the care provider blinded?   Yes   No  Don’t know/NA 
Were study personnel blinded?   Yes   No  Don’t know 
Was knowledge of allocated interventions adequately prevented?  
 Yes  No  Unclear 
 
• Incomplete Outcome Data   
Description of drop-outs:    Yes  No   No drop-outs 
 
Reason for drop-out      
Unable to contact      
Participant Withdrawal       
Other specified reasons 
Adverse events 
Protocol non-compliance 
Lack of efficacy 
Ineligible 
Scheduled withdrawal  
     
Reasons unspecified      
TOTAL      
 
Significant baseline between-group differences?   Yes (please specify)  No  Unclear 
Intention-to-treat analysis:  Yes   No   Unclear 
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Incomplete outcome data adequately addressed?   Yes  No  Unclear 
 
• Free of selective outcome reporting?  Yes     No (please specify)  Unclear 
Free of other bias?   Yes  No (please specify)  Unclear 
Results 
Baseline total number of participants: 
Number of participants allocated to treatment: 
Baseline data on participants 
     
Total number     
Mean age (sd)     
% of females     
Weight (SD)     
Mean duration of physical illness in 
years (sd) 
    
N. Prior DMARDS     
Mean MTX dose     
Corticosteroid use (%)     
Prior anti-TNF (%)     
RF+ (%)     
DAS28     
TJC     
SJC     
Pain VAS     
PGA     
AGA     
HAQ     
Morning stiffness     
CRP     
ESR     
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Treatment   Control 
PCS   
Mean score (sd)     
MCS   
Mean score (sd)     
PF    
Mean score (sd) / median 
(IQR) 
  
 
BP  
Mean score (sd) / median 
(IQR) 
  
 
RP  
Mean score (sd) / median 
(IQR) 
  
 
GH  
Mean score (sd) / median 
(IQR) 
  
 
VT  
Mean score (sd) / median 
(IQR) 
  
 
RE  
Mean score (sd) / median 
(IQR) 
  
 
SF  
Mean score (sd) / median 
(IQR) 
  
 
MH  
Mean score (sd) / median 
(IQR) 
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Time at t1 (number of weeks): 
Time at t2 (number of weeks): 
Time at t3 (number of weeks): 
Time at t4 (number of weeks): 
Time at t5 (number of weeks): 
Time at t6 (number of weeks): 
Time at t7 (number of weeks): 
Time at t8 (number of weeks): 
 
Drop-outs 
Number of drop-outs at t1  
Number of drop-outs at t2  
Number of drop-outs at t3  
Number of drop-outs at t4  
Number of drop-outs at t5  
Number of drop-outs at t6  
Number of drop-outs at t7  
Number of drop-outs at t8  
 
 
Outcome measures  
 Treatment  Control p 
PCS 
T1 – total number     
T1 – mean score (sd)      
T2 – total number     
T2 – mean score (sd)      
T2 mean change (SD)     
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T3 – total number     
T3 – mean score (sd)      
T2 mean change (SD)     
MCS 
 Treatment  Control p 
T1 – total number     
T1 – mean score (sd)      
T2 – total number     
T2 – mean score (sd)      
T2 mean change (SD)     
T3 – total number     
T3 – mean score (sd)      
T2 mean change (SD)     
 
Were point estimates and measures of variability  Yes   No  Don’t know 
Presented for the primary outcome measures? 
 
 
 
 
  
 
  
Any Other Outcomes: 
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Web-Appendix 4: Risk of bias and GRADE 
Study ID 
Random 
Sequence 
Generation 
Allocation 
concealment 
Blinding of 
participants 
and 
personnel 
Blinding of 
outcome 
assessment 
Incomplete 
Outcome 
Data 
Selective 
Reporting 
ADACTA Low Low Low Low Low High 
AIM Low Low Low Low Low High 
Alemao 2014 Unclear Unclear Unclear Unclear Unclear Unclear 
AMPLE Unclear High High Low High Low 
APPEAL Low Unclear High Unclear Low Low 
ATTAIN Unclear Low Low Low Low Low 
ATTEST Unclear Unclear Low Low Low Low 
ATTRACT Unclear Unclear High High Unclear Unclear 
AVERT Unclear Low Low Low Low High 
BEST Low Low High Low Unclear Low 
Burmester 2013 Unclear Unclear Unclear Unclear Unclear Unclear 
CERTAIN Low  Low Low Low Low Low 
Choy 2012 Low Low Low Low Low Low 
COMET Low Low Low Low Low Low 
CONCERTO Low Low Low Low Low Low 
Damjanov 2016 Unclear Unclear Low Low Low Low 
DANCER Unclear Unclear Low Low High Low 
Durez 2004 Unclear Unclear High High Unclear Low 
Emery 2006 Unclear Unclear Low Low Low Low 
FAST4WARD Low Low Low Low Low High 
FUNCTION Unclear Unclear Low Low High Low 
Genovese 2004 Unclear Unclear Low Low Low High 
GO-FORWARD Low Low Low Low Low Low 
GO-FURTHER Low Low Low Low Low Low 
HERA Low Low Low Low Low Low 
HIKARI Low Low High Low Low Low 
HIT HARD Unclear Unclear Low Low Low Low 
IMAGE Unclear Unclear Low Low Low Low 
J-RAPID Low Low Low Low Low Low 
Keystone 2004 Unclear Unclear Low Low Low Low 
Kim 2013 Unclear Unclear Low Low Low High 
Kremer 2003 Low Low Low Low Low Low 
Kremer 2014 Unclear Unclear Unclear Unclear Unclear High 
Li 2016 Unclear Unclear Low Low Low Low 
Machado 2014 Low Low High High Low Low 
Manders 2015 Low  Unclear High High Low High 
Mathias 2000 Unclear Unclear Low Low Low Low 
Mease 2012 Unclear Unclear Low Low Low Low 
MUSICA Unclear Unclear Low Unclear Unclear Low 
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OPERA Low Low Low Low Low Low 
OPTION Low Low Low Low Low Low 
ORAL Low Low Low Low Low Low 
ORAL-SCAN Low Unclear Low Low High Low 
ORAL-
STANDARD Low Low Low Low High Low 
ORAL-START Low Low Low Low High Low 
ORBIT Low Low High High Low Low 
PLANETRA Unclear Unclear Low Low Low Low 
PREMIER Unclear Unclear Low Low Low Low 
PRIZE Unclear Low Low Low Low High 
RA-BEACON Unclear Unclear Low Low Low Low 
RA-BEAM Unclear Unclear Low Low Low Low 
RADIATE Unclear Unclear Low Low High Low 
RA-MOBILITY Unclear Unclear Low Low Low Low 
RAPID1 Unclear Unclear Low Low Low Low 
RAPID2 Unclear Unclear Low Low Low Low 
REFLEX Unclear Unclear Low Low Low Low 
SERENE Unclear Unclear Low Low High Low 
SIRROUND-D Unclear Unclear Low Low Unclear Unclear 
SIRROUND-T Low Low Low Low Low Low 
Smolen 2012 Unclear Unclear Unclear Unclear Unclear Low 
Smolen 2014a Low Low Low Low Low Low 
Smolen 2014b Low Low Low Low Low Low 
St Clair 2004 Low Low Low Low Low High 
START Low Low Low Low Low High 
Strand 2011 Unclear Unclear Unclear Unclear High Low 
Strand 2012 Unclear Unclear Unclear Unclear Unclear Unclear 
Strand 2013 Unclear Unclear Unclear Unclear Low Unclear 
TACIT Low Low High High Low Low 
TASKi-2 Unclear Unclear Low Low Low Low 
TOWARD Unclear Unclear Low Low Low High 
Westhovens 2009 Unclear Unclear Low Low Low Low 
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GRADE results 
.  
 
 
  
 
 
 
Quality assessment Effect Quality 
N participants 
(studies) included Design Risk of bias Inconsistency Indirectness Imprecision 
Publication 
bias SMD (95%CI) 
 MCS 
23,535 (57) PMA Moderate Moderate 
No serious 
indirectness 
No serious 
imprecision None 0.24 (0.19-0.29) Moderate 
PCS 
       
23,108 (55) PMA Moderate Moderate 
No serious 
indirectness 
No serious 
imprecision None 0.47 (0.41-0.52) Moderate 
RCT randomised controlled trial. MCS mental component summary. PCS physical component summary. PMA pairwise meta-analysis 
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Web-Appendix 5: Network of comparisons included in NMA, 
comparator-adjusted funnel plots, forest plots and SUCRA graphs 
 
Network of comparisons 
 
 
 
Node (circles) sizes indicate the number of patients randomly assigned to each treatment, 
and the width of the lines represent the number of trials involving direct comparisons  
Page 55 of 68
John Wiley & Sons
Arthritis & Rheumatology
For Peer Review
Mental Component Summary 
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Physical Component Summary 
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Web-Appendix 6: Full references of studies identified via 
systematic review 
 
 
ADACTA Kavanaugh A, Emery P, Van Vollenhoven RF, et al. Tocilizumab Monotherapy 
Compared with Adalimumab Monotherapy in Patients with Rheumatoid Arthritis: 
Results of a 24-Week Study - ACR Meeting Abstracts. Arthritis Rheum. 
2012;:333–4 (abstr).http://acrabstracts.org/abstract/tocilizumab-monotherapy-
compared-with-adalimumab-monotherapy-in-patients-with-rheumatoid-arthritis-
results-of-a-24-week-study/ (accessed 9 Aug 2017). 
AIM Kremer JM, Genant HK, Moreland LW, et al. Effects of abatacept in patients with 
methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern 
Med 2006;144:865–76.http://www.ncbi.nlm.nih.gov/pubmed/16785475 
(accessed 9 Aug 2017). 
Alemao 
2014 
Alemao E, Joo S, Banerjee S, et al. AB0423 Impact of Anti-IL-6 Monoclonal 
Antibody, Clazakizumab, on Patient-Reported Outcomes in Patients with 
Rheumatoid Arthritis and an Inadequate Response to Methotrexate in A Phase 
Iib Study. Ann Rheum Dis 2014;73:947.1–947. doi:10.1136/annrheumdis-2014-
eular.1515 
AMPLE Fleischmann R, Weinblatt M, Schiff M, et al. SAT0129 Improved Quality of Life, 
Work Productivity, General Activity and Independence in Response to 
Subcutaneous Abatacept or Adalimumab in Rheumatoid Arthritis: Results from 
the Ample Trial. Ann Rheum Dis 2013;72:A624.3–A625. 
doi:10.1136/annrheumdis-2013-eular.1855 
 Fleischmann R, Weinblatt ME, Schiff M, et al. Patient-Reported Outcomes From 
a Two-Year Head-to-Head Comparison of Subcutaneous Abatacept and 
Adalimumab for Rheumatoid Arthritis. Arthritis Care Res (Hoboken) 
2016;68:907–13. doi:10.1002/acr.22763 
APPEAL Bae S-C, Gun SC, Mok CC, et al. Improved health outcomes with Etanercept 
versus usual DMARD therapy in an Asian population with established 
rheumatoid arthritis. BMC Musculoskelet Disord 2013;14:13. doi:10.1186/1471-
2474-14-13 
ATTAIN Westhovens R, Cole JC, Li T, et al. Improved health-related quality of life for 
rheumatoid arthritis patients treated with abatacept who have inadequate 
response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre 
randomized clinical trial. Rheumatology 2006;45:1238–46. 
doi:10.1093/rheumatology/kel066 
ATTEST Schiff M, Keiserman M, Codding C, et al. Efficacy and safety of abatacept or 
infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-
blind, placebo-controlled study in patients with rheumatoid arthritis and an 
inadequate response to methotrexate. Ann Rheum Dis 2008;67:1096–103. 
ATTRACT Maini RN, Breedveld FC, Kalden JR, et al. Sustained improvement over two 
years in physical function, structural damage, and signs and symptoms among 
patients with rheumatoid arthritis treated with infliximab and methotrexate. 
Arthritis Rheum 2004;50:1051–65. doi:10.1002/art.20159 
AVERT Emery P, Burmester GR, Bykerk VP, et al. Evaluating drug-free remission with 
abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, 
randomised, active-controlled AVERT study of 24 months, with a 12-month, 
double-blind treatment period. Ann Rheum Dis 2015;74:19–26. 
doi:10.1136/annrheumdis-2014-206106 
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BEST van der Kooij SM, de Vries-Bouwstra JK, Goekoop-Ruiterman YPM, et al. 
Patient-reported outcomes in a randomized trial comparing four different 
treatment strategies in recent-onset rheumatoid arthritis. Arthritis Care Res 
(Hoboken) 2008;61:4–12. doi:10.1002/art.24367 
Burmester 
2013 
Burmester GR, Tsutomu T, Barbarash O, et al. Early and sustained 
improvement in pain and physical function as measured by visual analog scale 
and Short Form-36 physical component summary score in rheumatoid arthritis 
patients treated with mavrilimumab, an investigational anti-GM-CSFR-alpha 
monoclona. In: 2013 ACR/ARHP Annual Meeting. 2013. 
doi:http://acrabstracts.org/abstract/early-and-sustained-improvement-in-pain-
and-physical-function-as-measured-by-visual-analog-scale-and-short-form-36-
physical-component-summary-score-in-rheumatoid-arthritis-patients-treated-
with-mavril/ 
 Burmester GR, McInnes IB, Kremer J, et al. A randomised phase IIb study of 
mavrilimumab, a novel GM–CSF receptor alpha monoclonal antibody, in the 
treatment of rheumatoid arthritis. doi:10.1136/annrheumdis-2016-210624 
CERTAIN Smolen JS, Emery P, Ferraccioli GF, et al. Certolizumab pegol in rheumatoid 
arthritis patients with low to moderate activity: the CERTAIN double-blind, 
randomised, placebo-controlled trial. Ann Rheum Dis 2015;74:843–50. 
Choy 2012 Choy E, McKenna F, Vencovsky J, et al. Certolizumab pegol plus MTX 
administered every 4 weeks is effective in patients with RA who are partial 
responders to MTX. Rheumatology 2012;51:1226–34. 
doi:10.1093/rheumatology/ker519 
COMET Kekow J, Moots RJ, Emery P, et al. Patient-reported outcomes improve with 
etanercept plus methotrexate in active early rheumatoid arthritis and the 
improvement is strongly associated with remission: the COMET trial. Ann 
Rheum Dis 2010;69:222–5. doi:10.1136/ard.2008.102509 
CONCER
TO 
Fleischmann R, Kivitz A, van Vollenhoven RF, et al. No differences in patient-
reported outcomes by methotrexate dose among early rheumatoid arthritis 
patients treated concomitantly with adalimumab: Results from the concerto trial. 
Ann Rheum Dis 2013;72:A580–1. doi:10.1136/annrheumdis-2013-aular.1732 
Damjanov 
2016 
Damjanov N, Tlustochowicz M, Aelion J, et al. Safety and Efficacy of SBI-087, a 
Subcutaneous Agent for B Cell Depletion, in Patients with Active Rheumatoid 
Arthritis: Results from a Phase II Randomized, Double-blind, Placebo-controlled 
Study. J Rheumatol 2016;43:2094–100. doi:10.3899/jrheum.160146 
DANCER Mease PJ, Revicki DA, Szechinski J, et al. Improved health-related quality of life 
for patients with active rheumatoid arthritis receiving rituximab: Results of the 
Dose-Ranging Assessment: International Clinical Evaluation of Rituximab in 
Rheumatoid Arthritis (DANCER) Trial. J Rheumatol 2008;35:20–
30.http://www.ncbi.nlm.nih.gov/pubmed/18050385. 
Durez 
2004 
Durez P, Nzeusseu Toukap A, Lauwerys BR, et al. A randomised comparative 
study of the short term clinical and biological effects of intravenous pulse 
methylprednisolone and infliximab in patients with active rheumatoid arthritis 
despite methotrexate treatment. Ann Rheum Dis 2004;63:1069–74. 
doi:10.1136/ard.2003.012914 
Emery 
2006 
Emery P, Kosinski M, Li T, et al. Treatment of rheumatoid arthritis patients with 
abatacept and methotrexate significantly improved health-related quality of life. J 
Rheumatol 2006;33:681–9.http://www.ncbi.nlm.nih.gov/pubmed/16568505. 
FAST4WA
RD 
Fleischmann R, Vencovsky J, van Vollenhoven RF, et al. Efficacy and safety of 
certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid 
arthritis failing previous disease-modifying antirheumatic therapy: the 
FAST4WARD study. Ann Rheum Dis 2009;68:805–11. 
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FUNCTIO
N 
Burmester G, Blanco R, Keiserman M, et al. Tocilizumab (TCZ) as combination 
therapy and as monotherapy vs methotrexate (MTX) in MTX-naive patients with 
early rheumatoid arthritis: Patient-reported outcomes (PROS) from a 
randomized, placebo-controlled trial. Ann Rheum Dis 2014;73:672. 
Genovese 
2004 
Genovese MC, Cohen S, Moreland L, et al. Combination therapy with 
etanercept and anakinra in the treatment of patients with rheumatoid arthritis 
who have been treated unsuccessfully with methotrexate. Arthritis Rheum 
2004;50:1412–9. doi:10.1002/art.20221 
GO-
FORWAR
D 
Genovese MC, Han C, Keystone EC, et al. Effect of Golimumab on Patient-
reported Outcomes in Rheumatoid Arthritis: Results from the GO-FORWARD 
Study. J Rheumatol 2012;39:1185–91. doi:10.3899/jrheum.111195 
GO-
FURTHER 
Bingham CO, Weinblatt M, Han C, et al. The Effect of Intravenous Golimumab 
on Health-related Quality of Life in Rheumatoid Arthritis: 24-week Results of the 
Phase III GO-FURTHER Trial. J Rheumatol 2014;41:1067–76. 
doi:10.3899/jrheum.130864 
HERA Bae S-C, Kim J, Choe J-Y, et al. A phase III, multicentre, randomised, double-
blind, active-controlled, parallel-group trial comparing safety and efficacy of 
HD203, with innovator etanercept, in combination with methotrexate, in patients 
with rheumatoid arthritis: the HERA study. Ann Rheum Dis 2016;76:1–7. 
HIKARI Yamamoto K, Takeuchi T, Yamanaka H, et al. Efficacy and safety of 
certolizumab pegol without methotrexate co-administration in Japanese patients 
with active rheumatoid arthritis: The HIKARI randomized, placebo-controlled 
trial. Mod Rheumatol 2014;24:552–60. doi:10.3109/14397595.2013.843764 
HIT HARD Detert J, Bastian H, Listing J, et al. Induction therapy with adalimumab plus 
methotrexate for 24 weeks followed by methotrexate monotherapy up to week 
48 versus methotrexate therapy alone for DMARD-naïve patients with early 
rheumatoid arthritis: HIT HARD, an investigator-initiated study. Ann Rheum Dis 
2013;72:844–50. doi:10.1136/annrheumdis-2012-201612 
IMAGE Rigby W, Ferraccioli G, Greenwald M, et al. Effect of rituximab on physical 
function and quality of life in patients with rheumatoid arthritis previously 
untreated with methotrexate. Arthritis Care Res (Hoboken) 2011;63:711–20. 
doi:10.1002/acr.20419 
J-RAPID Yamamoto K, Takeuchi T, Yamanaka H, et al. Efficacy and safety of 
certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients 
with an inadequate response to methotrexate: the J-RAPID randomized, 
placebo-controlled trial. Mod Rheumatol 2014;24:715–24. 
doi:10.3109/14397595.2013.864224 
Keystone 
2004 
Keystone EC, Kavanaugh AF, Sharp J, et al. Radiographic, clinical, and 
functional outcomes of treatment with adalimumab (a human anti-tumor necrosis 
factor monoclonal antibody) in patients with active rheumatoid arthritis receiving 
concomitant methotrexate therapy: a randomized, placebo-controlled. Arthritis 
Rheum 2004;50:1400–11. 
Kim 2013 Kim J, Ryu H, Yoo D-H, et al. A clinical trial and extension study of infliximab in 
Korean patients with active rheumatoid arthritis despite methotrexate treatment. 
J Korean Med Sci 2013;28:1716. doi:10.3346/jkms.2013.28.12.1716 
Kremer 
2003 
Kremer JM, Westhovens R, Leon M, et al. Treatment of rheumatoid arthritis by 
selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 
2003;349:1907–15. doi:http://dx.doi.org/10.1056/NEJMoa035075 
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Kremer 
2014 
Kremer JM, Burmester G, Weinblatt M, et al. Analysis of patient-reported 
outcomes during Treatment with Mavrilimumab, a Human Monoclonal Antibody 
Targeting GM-CSFRá, in the Randomized Phase 2b Earth Explorer 1 Study. 
Arthritis Rheumatol 2014;66:S653 
(abstr.).http://acrabstracts.org/abstract/analysis-of-patient-reported-outcomes-
during-treatment-with-mavrilimumab-a-human-monoclonal-antibody-targeting-
gm-csfra-in-the-randomized-phase-2b-earth-explorer-1-study. 
Li 2016 Li Z, Zhang F, Kay J, et al. Efficacy and safety results from a Phase 3, 
randomized, placebo-controlled trial of subcutaneous golimumab in Chinese 
patients with active rheumatoid arthritis despite methotrexate therapy. Int J 
Rheum Dis 2016;19:1143–56. doi:10.1111/1756-185X.12723 
Machado 
2014 
Machado DA, Guzman RM, Xavier RM, et al. Open-label observation of addition 
of etanercept versus a conventional disease-modifying antirheumatic drug in 
subjects with active rheumatoid arthritis despite methotrexate therapy in the 
Latin American region. J Clin Rheumatol 2014;20:25–33. 
doi:10.1097/RHU.0000000000000055 
Manders 
2015 
Manders SH, Kievit W, Adang E, et al. Cost-effectiveness of abatacept, 
rituximab, and TNFi treatment after previous failure with TNFi treatment in 
rheumatoid arthritis: a pragmatic multi-centre randomised trial. Arthritis Res Ther 
2015;17:134. doi:10.1186/s13075-015-0630-5 
Mathias 
2000 
Mathias SD, Colwell HH, Miller DP, et al. Health-related quality of life and 
functional status of patients with rheumatoid arthritis randomly assigned to 
receive etanercept or placebo. Clin Ther 2000;22:128–39. doi:10.1016/S0149-
2918(00)87984-9 
Mease 
2012 
Mease P, Strand V, Shalamberidze L, et al. A phase II, double-blind, 
randomised, placebo-controlled study of BMS945429 (ALD518) in patients with 
rheumatoid arthritis with an inadequate response to methotrexate. Ann Rheum 
Dis 2012;71:1183–9. 
MUSICA Kaeley GS, Nishio MJ, MacCarter D, et al. Similar Improvements in Physical 
Function, Quality of Life and Work Productivity Among Rheumatoid Arthritis 
Patients Treated with 2 Different Doses of Methotrexate  in Combination with 
Adalimumab - ACR Meeting Abstracts. In: Arthritis and Rheumatology. 2014. 
1042–3.http://acrabstracts.org/abstract/similar-improvements-in-physical-
function-quality-of-life-and-work-productivity-among-rheumatoid-arthritis-
patients-treated-with-2-different-doses-of-methotrexate-in-combination-with-
adalimumab/ 
OPERA Hørslev-Petersen K, Hetland ML, Junker P, et al. Adalimumab added to a treat-
to-target strategy with methotrexate and intra-articular triamcinolone in early 
rheumatoid arthritis increased remission rates, function and quality of life. The 
OPERA Study: an investigator-initiated, randomised, double-blind, parallel-
group, placebo-controlled trial. Ann Rheum Dis 2014;73:654–61. 
doi:10.1136/annrheumdis-2012-202735 
OPTION Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor 
inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a 
double-blind, placebo-controlled, randomised trial. Lancet 2008;371:987–97. 
doi:10.1016/S0140-6736(08)60453-5 
ORAL Strand V, Burmester GR, Zerbini CAF, et al. Tofacitinib With Methotrexate in 
Third-Line Treatment of Patients With Active Rheumatoid Arthritis: Patient-
Reported Outcomes From a Phase III Trial. Arthritis Care Res (Hoboken) 
2015;67:475–83. doi:10.1002/acr.22453 
ORAL-
SCAN 
Strand V, Van Der Heijde D, Zerbini CAF, et al. Oral scan: Effects of the oral 
JAK inhibitor tofacitinib in combination with methotrexate on patient reported 
outcomes in a 24-month phase 3 trial of active rheumatoid arthritis. Arthritis 
Rheum 2013;65:S996–
7.https://www.blackwellpublishing.com/acrmeeting/abstract.asp?MeetingID=799
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ORAL-
STANDAR
D 
Strand V, van Vollenhoven RF, Lee EB, et al. Tofacitinib or adalimumab versus 
placebo: patient-reported outcomes from a phase 3 study of active rheumatoid 
arthritis. Rheumatology 2016;55:1031–41. doi:10.1093/rheumatology/kev442 
ORAL-
START 
Strand V, Lee EB, Fleischmann R, et al. Tofacitinib versus methotrexate in 
rheumatoid arthritis: patient-reported outcomes from the randomised phase III 
ORAL Start trial. RMD Open 2016;2:e000308. doi:10.1136/rmdopen-2016-
000308 
 Strand V, Fleischmann R, Alten RE, et al. THU0258 Oral Start: Effects of the 
Oral JAK Inhibitor Tofacitinib Monotherapy Versus Methotrexate on Patient-
Reported Outcomes in the Phase 3 Oral Start Trial of Active Rheumatoid 
Arthritis. Ann Rheum Dis 2013;72:A252.3–A253. doi:10.1136/annrheumdis-
2013-eular.786 
ORBIT Porter D, van Melckebeke J, Dale J, et al. Tumour necrosis factor inhibition 
versus rituximab for patients with rheumatoid arthritis who require biological 
treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial. 
Lancet 2016;388:239–47. doi:10.1016/S0140-6736(16)00380-9 
PLANETR
A 
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Three studies did not have an appropriate design for inclusion in the meta-analyses [1-3] [6–
8], four did not have imputable data or data provided by the funders upon request [4-7] [9–
12], and one reported data from the HADS [8], making it incomparable with other studies, 
resulting in 8 studies included in the narrative synthesis.  
The BEST study [6] could not be included in the meta-analysis despite reporting sufficient 
SF36 data, due to the design of the trial. This trial compared outcomes from 4 stepped 
treatment strategies, with drug exposure depending on DAS28 treatment response: patients 
in group 1 could receive MTX, sulfasalazine (SSA), leflunomide, then MTX plus infliximab; 
patients in group 2 began with MTX, then MTX plus SSA plus hydroxychloroquine(HCQ), 
then MTX plus SSA plus HCQ plus prednisolone, then MTX plus infliximab; group 3 patients 
received MTX plus SSA + tapered prednisolone, then MTX plus ciclosporin and 
prednisolone, then MTX plus infliximab; patients in group 4 started with MTX + infliximab, 
then received SSA, then leflunomide. The results showed no significant between-group 
differences for MCS outcomes across all follow-up time points (12-104 weeks). 
Four studies examine the impact of anti-TNF treatments on mental health outcomes: the 
ATTRACT study [9] examining infliximab versus MTX plus placebo; CONCERTO trial [7] 
investigating different doses of MTX in addition to 40mg of adalimumab every other week; 
Keystone et al. [10] examining adalimumab versus MTX plus placebo; and the MUSICA trial 
[8] assessing of MTX in addition to 40mg of adalimumab every other week. Both ATTRACT 
and Keystone et al. report significant improvements in PCS scores over time, however whilst 
Keystone found significant differences between the adalimumab and control groups across 
all SF36 domains, the ATTRACT study reported no significant group differences in MCS 
outcomes. The CONERTO and MUSICA trials found similar improvements in all domains of 
HRQoL during the course of follow-up (26/24 weeks respectively), but noted no significant 
differences between different dose groups in relation to MCS or PCS outcomes.  
Strand 2012, in an abstract submitted to the 3rd world Psoriasis and Psoriatic Arthritis 
Conference in 2012, reports an increase in median PCS and MCS scores in patients 
receiving various doses of secukinumab (doses from 25-300mg per month), although 
median changes did not appear to significantly differ from the placebo group [12]. Kremer et 
al. [11] show graphs of mean change from baseline in all domains of the SF36 after 
exposure to either 2mg or 10mg of abatacept every 4 weeks. In comparison to the placebo 
control group, patients receiving 10mg of abatacept showed significantly increased change 
in all domains of the SF36 including the mental health subscale. 
The ORBIT trial [8] provided information suitable for inclusion in the meta-analysis, but was 
the only study to use the Hospital Anxiety Depression Scale (HADS; [9]), so was excluded 
from meta-analyses to reduce study heterogeneity. This study randomised 295 participants 
to receive rituximab or anti-TNF treatments. Analysis revealed no significant between-group 
differences in HADS depression or anxiety scores over a 1-year follow-up.  
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